15 completed, 5 terminated, 5 unknown, 3 recruiting. 21 Phase 2, 6 Phase 3, 4 Phase 1, 2 Phase 4, 1 Early Phase 1.
Follow Methoxsalen: new trials by email Literature Review of Methoxsalen trials Research Report on Methoxsalen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis Methoxsalen, Infliximab, Vedolizumab - Immune-related Colitis | Phase 2 | Withdrawn | Therakos LLC | 2025-12-15 | 2025-12-26 | |
| Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis Extracorporeal Photopheresis (ECP), UVADEX - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 15 | 2025-05-14 | 2026-10-01 |
| Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD Uvadex, Steroids - Graft Vs Host Disease | Phase 2 | Unknown | Central Hospital, Nancy, France | 42 | 2024-01-01 | 2023-11-15 |
| Extracorporeal Photopheresis in Sezary Syndrome Extracorporeal photopheresis (ECP), Methoxsalen Injection - Sezary Syndrome | Recruiting | Oleg E. Akilov, MD, PhD | 20 | 2023-04-04 | 2025-12-30 | |
| Photopheresis in Early-stage Mycosis Fungoides UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Recruiting | Columbia University | 74 | 2021-05-08 | 2026-04-27 |
| Study of Photopheresis in the Treatment of Erythrodermic MF and SS Methoxsalen, THERAKOS CELLEX Photopheresis System - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-12-01 | 2021-09-08 | |
| Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease Uvadex - Acute-graft-versus-host Disease | Phase 2 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 24 | 2020-05-18 | 2025-03-30 |
| SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) - Sarcoma, Ewing, Sarcoma | Phase 2 | Active not recruiting | Sarcoma Oncology Research Center, LLC | 31 | 2020-01-03 | 2025-02-24 |
| A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease Methoxsalen + ECP device, Corticosteroids - Acute-graft-versus-host Disease | Phase 2 | Unknown | Central Hospital, Nancy, France | 78 | 2018-10-01 | 2018-07-30 |
| A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU - Pancreatic Cancer | Phase 2 / Phase 3 | Terminated | Tyme, Inc | 130 | 2018-03-27 | 2024-11-06 |
| Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease Methoxsalen, Extracorporeal Photopheresis (ECP) - Steroid Refractory Acute Graft Versus Host Disease | Phase 3 | Terminated | Therakos, Inc., a Mallinckrodt Company | 29 | 2016-01-20 | 2020-09-11 |
| Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD Extracorporeal Photopheresis (ECP), Methoxsalen - Chronic Graft vs. Host Disease, Graft vs Host Disease | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2014-12-20 | 2020-03-12 |
| PUVA Maintenance Therapy in Mycosis Fungoides 8-methoxypsoralen - Patch/Plaque Stage Mycosis Fungoides | Phase 3 | Completed | Medical University of Graz | 28 | 2013-02-01 | 2018-11-14 |
| Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) ECP Methoxsalen, Standard of Care - Chronic Graft Versus Host Disease | Early Phase 1 | Completed | Mallinckrodt | 60 | 2011-11-01 | 2020-02-19 |
| Extracorporal Photopheresis Pilot Study methoxsalen, Extracoporal Photopheresis (ECP) - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Hospices Civils de Lyon | 20 | 2009-04-01 | 2013-04-24 |
| Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis) - Graft Versus Host Disease | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 48 | 2009-03-01 | 2017-08-01 |
| Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis 8-methoxypsoralen or 5- methoxypsoralen, 8-methoxypsoralen or 5methoxypsoralen - Pustular Palmoplantar Psoriasis | Phase 3 | Unknown | Medical University of Vienna | 20 | 2008-10-01 | 2009-09-18 |
| Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis 5-Methoxypsoralen, UVA1 phototherapy - Atopic Dermatitis | Phase 3 | Completed | Medical University of Vienna | 20 | 2007-10-01 | 2009-01-14 |
| Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes Cyclosporine, Methotrexate, Photopheresis - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Eastern Cooperative Oncology Group | 17 | 2006-10-24 | 2023-06-28 |
Showing 20 of 34. Sign in to see all of them.
Mycosis Fungoides (8) · Graft vs Host Disease (5) · Lymphoma, T-Cell, Cutaneous (5) · Sezary Syndrome (5) · Lymphoma (3) · Crohn Disease (2) · HIV Infections (2) · Hematologic Neoplasms (2) · Leukemia (2) · Leukemia, Myelomonocytic, Chronic (2) · Melanoma (2) · Myelodysplastic Syndromes (2) · Skin Diseases (2) · AIDS-Related Complex (1) · Anemia, Refractory (1)
Mallinckrodt (5) · Central Hospital, Nancy, France (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · M.D. Anderson Cancer Center (2) · Medical University of Vienna (2) · Therakos LLC (2) · Atlantic Health System (1) · Columbia University (1) · Eastern Cooperative Oncology Group (1) · Hospices Civils de Lyon (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Madrilenian Group of Cutaneous Lymphomas (1) · Medical University of Graz (1) · Millennix (1) · National Cancer Institute (NCI) (1)
United States (20) · Austria (10) · Germany (8) · France (7) · Italy (6) · Spain (5) · United Kingdom (5) · Australia (3) · Belgium (3) · Hungary (3) · Slovakia (3) · Switzerland (3) · Canada (2) · Portugal (2) · Turkey (Türkiye) (2)
Adrian Tanew, MD (1) · Adrian Tanew, Prof. MD (1) · Dr. Janet E Pope, MD PhD (1) · Emil Bisaccia, MD (1) · Francine Foss, M.D. (1) · Francis A. Ayuk, Prof. Dr. (1) · Franz Trautinger (1) · Giuseppe DelPriore, MD, MPH (1) · Gregory Yanik, MD (1) · Isabelle T Seemann, Ph.D (1) · James Gajewski, MD (1)
PMID 32632956, PMID 18621929, PMID 21575927, PMID 22924950, PMID 30892603, PMID 31332045, PMID 32850876, PMID 35499204
2004 (1), 2017 (1), 2018 (1), 2023 (1), P30CA016672 (1), U10CA021115 (1)